Why the study?
Do the verapamil analogues anipamil and ronipamil reduce ischaemia-induced arrhythmias in conscious rats?
Do the verapamil analogues anipamil and ronipamil reduce ischaemia-induced arrhythmias in conscious rats?
Anipamil, a verapamil analogue, significantly reduces ischaemia-induced arrhythmias and delays ECG signs of ischaemia in a rat model, with a more favorable antiarrhythmic to hypotensive ratio than verapamil.
May support anipamil development for ischaemic arrhythmias; leaves open translation from rat models to patients.
Two analogues of verapamil, ronipamil and anipamil, were tested for their ability to reduce arrhythmias induced by occlusion of the left anterior descending coronary artery in conscious rats. Only anipamil (50 and 150 mg kg-1 orally) produced a statistically significant reduction in arrhythmias; it was most effective against ventricular fibrillation. Ronipamil at the same doses had limited antiarrhythmic actions. Only anipamil delayed the development of ECG signs of ischaemia, while both drugs reduced the magnitude of such changes. Anipamil has a more favourable ratio of antiarrhythmic to hypotensive effects when compared with verapamil.
No takes yet. Share an insight, caveat, or question.
Curtis et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: